Russia will supply Mexico with 32 million doses of its COVID-19 vaccine, Sputnik V, come November.
The announcement came after The Russian Direct Investment Fund (RDIF) and the Landsteiner Scientific, a Mexican pharmaceutical company agreed to supply these doses to around 25% of the Mexican population.
Landsteiner Scientific will be in charge of distributing the vaccine in Mexico.
According to Kirill Dmitriev, CEO of the RDIF, their Mexican partners have a clear understanding of Spuitnik’s safety, along with its advantage compared to other vaccine candidates around.
As per a recent study, 66% of Mexicans expressed their confidence in Sputnik V, Dmitriev said.
Updates On Sputnik V
The Gamaleya National Research Institute of Epidemiology and Microbiology in Moscow registered Sputnik V in Russia’s Ministry of Health on August 11th.
It was the first registered vaccine for COVID-19.
Early this month, Russia announced it is ready to test its efficacy on people and had it disseminated to the Russian public.
According to a September 4th research paper on the results of its Phase 1 and Phase 2 trials, there were no negative and serious effects among the participants of the test.
Also, there was a stable immune response in all of its participants, as per RDIF.
Currently, around 40,000 volunteers are involved in its post-registration clinical trials, the results will be published sometime in October or November.
According to RDIF, the Sputnik V is based on the human adenoviral vectors platform.
So far, more than 70 international publications and more than 200 clinical trials have proven the platform’s safety.
Controversies Around It
Some countries have raised their concerns about Sputnik V, citing its fast clinical trials and approval as compromising its safety.
However, the World Health Organization (WHO) announced last month that they are looking forward to reviewing the vaccine made by Russia.
The Philippines will be the first country outside Russia to receive it, Philippine Rodrigo Duterte announced last month.